search
for
 About Bioline  All Journals  Testimonials  Membership  News


Australasian Biotechnology (backfiles)
AusBiotech
ISSN: 1036-7128
Vol. 12, No. 5, 2002, pp. 37-38
Bioline Code: au02031
Full paper language: English
Document type: Research Article
Document available free of charge

Australasian Biotechnology (backfiles), Vol. 12, No. 5, 2002, pp. 37-38

 en BIOTECH R&D - Biotechnology Companies - Is the R&D Tax Offset a Genuine Option?
Susanna Muttilainen & Alun Needham

Abstract

This article is a follow up to our New Incentives for R&D - Recent Changes to R&D Tax Concession article published in the August/September 2002 edition of Australasian Biotechnology. In particular, this article focuses on the new R&D Tax Offset, which allows eligible companies to receive a cash rebate equivalent to the value of the R&D Tax Concession.

This is an initiative welcomed by small companies across most industry sectors, encouraging higher levels of expenditure on R&D. However, there are concerns that some companies in the biotechnology sector will fail to qualify for the Offset because they are spending too much on eligible R&D activities or have an ownership structure that is in breach of the requirements. This article discusses these issues in detail as well as providing suggestions as to how the Offset might be made of value to more biotechnology companies.

 
© Copyright 2002 - AusBiotech
Alternative site location: http://www.ausbiotech.org/content.asp?pageid=16

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil